Literature DB >> 20542127

Intranigral transplantation of epigenetically induced BDNF-secreting human mesenchymal stem cells: implications for cell-based therapies in Parkinson's disease.

Rodrigo Somoza1, Carlos Juri, Mauricio Baes, Ursula Wyneken, Francisco Javier Rubio.   

Abstract

It is thought that the ability of human mesenchymal stem cells (hMSC) to deliver neurotrophic factors might be potentially useful for the treatment of neurodegenerative disorders. The aim of the present study was to characterize signals and/or molecules that regulate brain-derived neurotrophic factor (BDNF) protein expression/delivery in hMSC cultures and evaluate the effect of epigenetically generated BDNF-secreting hMSC on the intact and lesioned substantia nigra (SN). We tested 4 different culture media and found that the presence of fetal bovine serum (FBS) decreased the expression of BDNF, whereas exogenous addition of epidermal growth factor (EGF) and basic fibroblast growth factor (bFGF) to serum-free medium was required to induce BDNF release (125 ± 12 pg/day/10⁶ cells). These cells were called hM(N)SC. Although the induction medium inhibited the expression of alpha smooth muscle actin (ASMA), an hMSC marker, and increased the nestin-positive subpopulation of hMSC cultures, the ability to express BDNF was restricted to the nestin-negative subpopulation. One week after transplantation into the SN, the human cells integrated into the surrounding tissue, and some showed a dopaminergic phenotype. We also observed the activation of Trk receptors for neurotrophic factors around the implant site, including the BDNF receptor TrkB. When we transplanted these cells into the unilateral lesioned SN induced by striatal injection of 6-hydroxydopamine (6-OHDA), a significant hypertrophy of nigral tyrosine hydroxylase (TH)(+) cells, an increase of striatal TH-staining and stabilization of amphetamine-induced motor symptoms were observed. Therefore, hMSC cultures exposed to the described induction medium might be highly useful as a vehicle for neurotrophic delivery to the brain and specifically are strong candidates for future therapeutic application in Parkinson's disease.
Copyright © 2010 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20542127     DOI: 10.1016/j.bbmt.2010.06.006

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  18 in total

1.  The TrkB-positive dopaminergic neurons are less sensitive to MPTP insult in the substantia nigra of adult C57/BL mice.

Authors:  Yin-Xiu Ding; Yi Xia; Xi-Ying Jiao; Li Duan; Jun Yu; Xi Wang; Liang-Wei Chen
Journal:  Neurochem Res       Date:  2011-05-12       Impact factor: 3.996

Review 2.  Neurotrophin strategies for neuroprotection: are they sufficient?

Authors:  Joseph P Steiner; Avindra Nath
Journal:  J Neuroimmune Pharmacol       Date:  2014-03-08       Impact factor: 4.147

Review 3.  Great promise of tissue-resident adult stem/progenitor cells in transplantation and cancer therapies.

Authors:  Murielle Mimeault; Surinder K Batra
Journal:  Adv Exp Med Biol       Date:  2012       Impact factor: 2.622

Review 4.  Advances in treatment of neurodegenerative diseases: Perspectives for combination of stem cells with neurotrophic factors.

Authors:  Jie Wang; Wei-Wei Hu; Zhi Jiang; Mei-Jiang Feng
Journal:  World J Stem Cells       Date:  2020-05-26       Impact factor: 5.326

5.  Neurotensin-polyplex-mediated brain-derived neurotrophic factor gene delivery into nigral dopamine neurons prevents nigrostriatal degeneration in a rat model of early Parkinson's disease.

Authors:  Nancy G Hernandez-Chan; Michael J Bannon; Carlos E Orozco-Barrios; Lourdes Escobedo; Sergio Zamudio; Fidel De la Cruz; Jose L Gongora-Alfaro; Juan Armendáriz-Borunda; David Reyes-Corona; Armando J Espadas-Alvarez; Yazmin M Flores-Martínez; Jose Ayala-Davila; Maria E Hernandez-Gutierrez; Lenin Pavón; Refugio García-Villegas; Rasajna Nadella; Daniel Martinez-Fong
Journal:  J Biomed Sci       Date:  2015-07-22       Impact factor: 8.410

Review 6.  Stem cell transplantation in neurological diseases: improving effectiveness in animal models.

Authors:  Raffaella Adami; Giuseppe Scesa; Daniele Bottai
Journal:  Front Cell Dev Biol       Date:  2014-05-14

7.  Cell based therapy in Parkinsonism.

Authors:  Johannes Pjm de Munter; Chongsik Lee; Erik Ch Wolters
Journal:  Transl Neurodegener       Date:  2013-06-04       Impact factor: 8.014

8.  Delayed transplantation of precursor cell-derived astrocytes provides multiple benefits in a rat model of Parkinsons.

Authors:  Christoph Proschel; Jennifer L Stripay; Chung-Hsuan Shih; Joshua C Munger; Mark D Noble
Journal:  EMBO Mol Med       Date:  2014-01-29       Impact factor: 12.137

9.  From molecular to nanotechnology strategies for delivery of neurotrophins: emphasis on brain-derived neurotrophic factor (BDNF).

Authors:  Claire Géral; Angelina Angelova; Sylviane Lesieur
Journal:  Pharmaceutics       Date:  2013-02-08       Impact factor: 6.321

10.  Nogo-A Neutralization Improves Graft Function in a Rat Model of Parkinson's Disease.

Authors:  Stefanie Seiler; Stefano Di Santo; Hans Rudolf Widmer
Journal:  Front Cell Neurosci       Date:  2016-04-05       Impact factor: 5.505

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.